



April 2009

ETHYPHARM AND ARCHIMEDES EXPAND COLLABORATION ON MORPHINE IN EUROPE

ETHYPHARM today announced it has signed two agreements with the pan-European company Archimedes Pharma Limited, including a key distribution agreement for its morphine capsule once daily product, Zomorph®.

These agreements secure marketing and distribution rights for morphine once-a-day for the first time in several European countries, among which France, Belgium and Luxembourg and extend twice a day in some EU countries.

Morphine sulphate capsule (20, 40, 60, 120 and 200mg), is administered for the treatment of moderate to severe pain, particularly cancer pain. This pellet capsule is by far more flexible than previous tablet formulations : it is easier to swallow and can also be opened and sprinkled into food or drink or administered via a naso-gastric tube, thus overcoming the problems often associated with the use of tablets.

"We are very happy to announce this partnership with Archimedes, which is already the holder of our twice-a-day morphine capsule marketing and licensing rights" declared Bruno Delie, Ethypharm's Business & Marketing Director. "Moreover, Archimedes widespread portfolio in the field of pain treatment in hospitals makes it a key partner on European Union markets for Ethypharm", he added.

Regulatory approvals have been granted in all markets and product launches are expected to take place in 2009, subject to pricing and reimbursement approval.

About ETHYPHARM
www.ethypharm.com

Ethypharm is a pharmaceutical laboratory specialized in controlled release systems of medicinal products by the oral route. Its principal therapeutic fields concern pain relief, cardio-vascular and the central nervous system. The Company has more than 50 products launched by marketing partners of international repute in over 70 countries. Ethypharm develops and manufactures its products in compliance with the current world-wide pharmaceutical Norms. The Company has developed a wide range of technological platforms for the administration of medicinal products by the oral route, including extended release, taste-masked orodispersible forms and ameliorated solubility systems for active substances with low solubility. Ethypharm is present on the principal world health markets with its manufacturing plants and Research & Development centres in Europe, in the United States of America and in Asia. The Laboratory employs a world-wide work force of 850.

Ethypharm
194 Bureaux de la Colline
92 213 Saint-Cloud, France

Tel: +33 1 41 12 17 20
www.ethypharm.com